Overview

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
Efficacy and safety of Thymalfasin adjuvant therapy in HBV-related HCC after curative resection.
Phase:
Phase 4
Details
Lead Sponsor:
Jia Fan
Collaborator:
SciClone Pharmaceuticals
Treatments:
Entecavir
Thymalfasin